mHealth Market by Component (Connected Medical Devices, mHealth Apps, mHealth Services), Application (Chronic Disease Management, General Health & Fitness, Remote Consultation & Telemedicine), End-User - Global Forecast 2025-2032
Description
The mHealth Market was valued at USD 94.82 billion in 2024 and is projected to grow to USD 109.36 billion in 2025, with a CAGR of 16.17%, reaching USD 314.55 billion by 2032.
An orienting perspective on the evolving mHealth ecosystem where devices, applications, and services converge to redefine care delivery and patient engagement
The mHealth ecosystem is undergoing rapid convergence of clinical-grade devices, consumer applications, and integrated service models that extend care beyond traditional settings. Advances in sensor miniaturization, wireless interoperability, and user-centered design have enabled medical devices to function reliably in home and ambulatory environments, while apps are translating raw data into clinically useful signals through improved algorithms and context-aware interfaces. Meanwhile, service models that combine analytics, remote monitoring, and clinician workflows are maturing, creating new value pathways for providers and payers.
Against this backdrop, stakeholders must reconcile technological opportunity with practical constraints such as usability, data governance, and clinical validation. Interoperability expectations are rising as care teams demand seamless data flows between devices, apps, and electronic health records. In addition, patient engagement paradigms are shifting toward longitudinal, outcome-oriented journeys that prioritize adherence and behavior change. Consequently, product development and commercialization strategies that emphasize evidence generation, integrated care pathways, and scalable service delivery are emerging as the critical levers for adoption.
Key structural shifts across regulation, reimbursement, data analytics, and consumer expectations that are accelerating adoption and creating strategic inflection points
Several transformative shifts are reshaping the landscape and creating new opportunities for innovation and disruption. First, regulatory pathways are adapting to software and connected devices, which is prompting product teams to integrate quality systems and clinical evidence generation early in development. Second, reimbursement and contracting models are evolving to reward outcomes and remote care, thereby aligning incentives for payers and providers to adopt digital-first care models. Third, advances in data analytics and edge computing are enabling more sophisticated real-time clinical decision support, which increases the clinical utility of remote monitoring and wearable data.
Furthermore, consumer expectations are influencing product design; patients now expect seamless experiences that mirror best-in-class consumer applications, which places a premium on interoperability, privacy controls, and accessible design. Strategic partnerships are increasingly central to growth strategies, as technology firms, medical device manufacturers, health systems, and payers form coalitions to combine capabilities across hardware, software, and services. Taken together, these shifts favor organizations that can align clinical credibility with scalable technology platforms and compelling user experiences.
How recent tariff dynamics are redirecting supply chain strategies and operational design choices across the connected health technology value chain
The imposition of tariffs and trade policy shifts has amplified supply chain scrutiny and stimulated reassessment of sourcing, manufacturing footprint, and component strategies across the mHealth ecosystem. Tariff-driven input cost pressure has encouraged manufacturers to evaluate nearshoring options, diversify supplier bases, and redesign product bill of materials to reduce exposure to affected components. In parallel, device OEMs and contract manufacturers are placing greater emphasis on supply chain resilience, inventory buffering, and alternative logistics routes to mitigate potential disruptions.
Beyond direct cost implications, tariffs influence strategic decisions that shape partnerships and go-to-market planning. For example, firms that depend on global components for sensors, wireless modules, or semiconductor subsystems are recalibrating procurement timelines and validating substitute suppliers to preserve design integrity. Service providers and app developers are also attentive to device availability and certification timelines because hardware constraints can delay deployments of integrated solutions. In response, many organizations are accelerating standardization initiatives, modularizing designs to accommodate component variability, and increasing transparency with customers about supply chain contingencies. Collectively, these responses reflect a broader industry pivot toward operational agility and geographically diversified supply strategies.
Deep segmentation intelligence describing components, clinical applications, and end-user behaviors to guide product prioritization and go-to-market strategies
A nuanced segmentation approach reveals differentiated adoption drivers and barriers across components, applications, and end users. When considering components, the market encompasses connected medical devices, mHealth apps, mHealth services, and wearable devices. Connected medical devices include subcategories such as blood glucose meters, blood pressure monitors, ECG and heart rate monitors, fetal monitoring devices, neurological monitoring devices, peak flowmeters, pulse oximeters, and sleep apnea monitors, each of which carries unique clinical validation and regulatory demands. mHealth apps span chronic disease management, medication management, personal health records, and women’s health, with chronic disease management further defined by blood pressure and ECG monitoring apps, cancer management apps, diabetes management apps, mental health management apps, and obesity management apps. Women’s health apps cover menstrual health and pregnancy tracking plus postpartum care. mHealth services encompass diagnosis and consultation services, fitness and wellness services, prevention services, remote monitoring services, and treatment services. Wearable devices are largely represented by fitness trackers and smart watches that blend consumer convenience with clinically relevant sensing.
Application-focused segmentation highlights chronic disease management, general health and fitness, remote consultation and telemedicine, and women’s health as distinct demand contexts. Chronic disease management itself includes asthma management, cardiovascular disease management, and diabetes management, each requiring tailored clinical workflows, integration with care teams, and evidence of clinical effectiveness. Women's health applications address menopause management, menstrual health, and pregnancy tracking, where privacy, cultural considerations, and longitudinal data continuity are paramount. From an end-user perspective, stakeholders include healthcare payers, healthcare providers, and patients, with providers comprised of clinic and hospital settings; each end user values different outcomes ranging from cost containment and population health metrics to individual engagement and clinical workflow efficiency. By synthesizing these segmentation lenses, product and commercial strategies can be aligned to match specific clinical use cases, regulatory thresholds, and buyer motivations.
Regional dynamics and operational considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and commercialization success
Regional dynamics reveal diverse opportunity sets and regulatory landscapes that shape commercialization and operational choices. In the Americas, market dynamics are driven by integrated payer-provider systems, a focus on value-based care models, and heavy investment in telehealth infrastructure; stakeholders here prioritize interoperability with existing electronic health records and evidence generation that supports reimbursement conversations. Europe, Middle East & Africa presents a patchwork of national regulatory approaches and procurement mechanisms where privacy regulations and national health system priorities can affect adoption timelines; innovative reimbursement pilots often coexist with conservative procurement cycles, making local partnerships and clinical champions crucial for scaling. Asia-Pacific exhibits heterogeneous maturity across markets, with advanced digital health ecosystems in some high-income markets and rapid adoption of mobile-first health services in emerging economies, where scalability and cost-efficient deployment are central considerations.
Consequently, regional go-to-market strategies should factor in local regulatory frameworks, reimbursement pathways, and health system architectures. In addition, cultural expectations around data privacy and patient engagement must be addressed through localized user experience design and transparent governance practices. Strategic entrants will often adopt a phased approach, demonstrating clinical impact in targeted geographies before scaling broadly, while also investing in regional partnerships to navigate distribution, certification, and payer negotiation complexities.
Corporate strategic patterns revealing how clinical validation, partnerships, and platform architectures are shaping competitive advantage among mHealth providers
Companies across the mHealth landscape are differentiating through a combination of clinical credibility, platform scale, and partnership ecosystems. Market incumbents emphasize regulatory compliance and integrated hardware-software offerings to serve clinical workflows, investing in long-form clinical validation and payer engagement. Agile technology companies are focusing on modular software platforms, developer ecosystems, and rapid iteration to capture developer mindshare and integrate with diverse device makers. Start-ups typically pursue focused use cases where a narrow clinical question or user need enables faster evidence generation and customer acquisition.
Strategic moves include cross-sector collaborations that combine device expertise with analytics and care management capabilities, as well as licensing or OEM relationships that embed software in partner devices. Investment in clinical studies, real-world evidence generation, and interoperability certifications continues to be a critical differentiator for companies seeking widespread adoption. Additionally, firms that deliver repeatable service models and strong implementation playbooks for providers and payers are better positioned to translate pilot success into long-term contracts. Ultimately, the competitive landscape rewards organizations that can bridge clinical rigor with operational scalability and compelling patient experiences.
Practical strategic imperatives for market leaders to scale evidence, ensure interoperability, and build resilient supply and partnership models for long-term growth
Industry leaders should prioritize several actionable moves to convert market momentum into sustainable growth. First, establish cross-functional clinical evidence programs that integrate regulatory strategy, health economics, and real-world data collection from the outset, thereby reducing time to credible adoption by providers and payers. Second, design product architectures that separate hardware-dependent functionality from cloud-based analytics so that modular updates and supplier substitutions can be executed without major redesign. Third, cultivate payer and provider partnerships through pilot programs that demonstrate measurable outcomes and operational feasibility, and use these pilots to co-create reimbursement pathways.
In addition, focus on interoperability and standards adoption to reduce integration friction with electronic health records and device management platforms, and invest in privacy-by-design principles to build patient trust. From an operational standpoint, diversify supplier relationships and explore regional sourcing strategies to mitigate trade-related risks while retaining manufacturing quality. Finally, invest in user experience and behavioral design to maximize adherence and engagement, because even clinically effective solutions will fail to deliver value if patients do not sustain use. Executing on these priorities will require aligned leadership, cross-disciplinary capabilities, and disciplined program management.
A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory review, and cross-regional analysis to produce action-oriented insights
The research methodology underpinning these insights integrates multi-source qualitative and quantitative approaches to capture technology, clinical, regulatory, and commercial dimensions. Primary interviews with clinicians, health system leaders, payers, and product leaders were triangulated with secondary sources, regulatory filings, and peer-reviewed literature to ensure balanced perspectives. An emphasis was placed on real-world implementation experiences and case-based learning to illuminate operational barriers and facilitators that are not always apparent in headline technology descriptions.
Analytical frameworks included segmentation mapping across component, application, and end-user dimensions, cross-regional comparative analysis to surface regulatory and market access differentials, and thematic synthesis of corporate strategies and partnership models. Data quality controls focused on corroborating claims across multiple stakeholder interviews and validating technical assertions with subject-matter experts. Where applicable, findings were stress-tested against plausible operational scenarios to assess sensitivity to supply chain disruptions, regulatory shifts, and changes in reimbursement practices. This mixed-methods approach aims to provide robust, action-oriented intelligence for decision-makers.
A strategic synthesis of clinical, technological, and operational priorities that will determine which organizations capture sustainable value in the evolving mHealth ecosystem
In conclusion, the mHealth landscape is at an inflection point where clinical-grade sensing, software intelligence, and service delivery models are coalescing to extend care across settings. The propensity for adoption will hinge on the ability of solutions to demonstrate clinical value, integrate seamlessly into care workflows, and maintain privacy and security assurances that earn stakeholder trust. Operational resilience, particularly in sourcing and supply chain design, has risen to the forefront of strategic planning due to trade dynamics and component concentration risks.
Moving forward, successful organizations will be those that combine rigorous evidence generation with modular technology architectures, robust partnerships across the care ecosystem, and localized go-to-market strategies that respect regional regulatory and cultural nuances. By aligning product development, clinical validation, and commercial models around demonstrated outcomes, companies can transition pilot successes into scalable deployments that deliver measurable benefits for patients, providers, and payers.
Please Note: PDF & Excel + Online Access - 1 Year
An orienting perspective on the evolving mHealth ecosystem where devices, applications, and services converge to redefine care delivery and patient engagement
The mHealth ecosystem is undergoing rapid convergence of clinical-grade devices, consumer applications, and integrated service models that extend care beyond traditional settings. Advances in sensor miniaturization, wireless interoperability, and user-centered design have enabled medical devices to function reliably in home and ambulatory environments, while apps are translating raw data into clinically useful signals through improved algorithms and context-aware interfaces. Meanwhile, service models that combine analytics, remote monitoring, and clinician workflows are maturing, creating new value pathways for providers and payers.
Against this backdrop, stakeholders must reconcile technological opportunity with practical constraints such as usability, data governance, and clinical validation. Interoperability expectations are rising as care teams demand seamless data flows between devices, apps, and electronic health records. In addition, patient engagement paradigms are shifting toward longitudinal, outcome-oriented journeys that prioritize adherence and behavior change. Consequently, product development and commercialization strategies that emphasize evidence generation, integrated care pathways, and scalable service delivery are emerging as the critical levers for adoption.
Key structural shifts across regulation, reimbursement, data analytics, and consumer expectations that are accelerating adoption and creating strategic inflection points
Several transformative shifts are reshaping the landscape and creating new opportunities for innovation and disruption. First, regulatory pathways are adapting to software and connected devices, which is prompting product teams to integrate quality systems and clinical evidence generation early in development. Second, reimbursement and contracting models are evolving to reward outcomes and remote care, thereby aligning incentives for payers and providers to adopt digital-first care models. Third, advances in data analytics and edge computing are enabling more sophisticated real-time clinical decision support, which increases the clinical utility of remote monitoring and wearable data.
Furthermore, consumer expectations are influencing product design; patients now expect seamless experiences that mirror best-in-class consumer applications, which places a premium on interoperability, privacy controls, and accessible design. Strategic partnerships are increasingly central to growth strategies, as technology firms, medical device manufacturers, health systems, and payers form coalitions to combine capabilities across hardware, software, and services. Taken together, these shifts favor organizations that can align clinical credibility with scalable technology platforms and compelling user experiences.
How recent tariff dynamics are redirecting supply chain strategies and operational design choices across the connected health technology value chain
The imposition of tariffs and trade policy shifts has amplified supply chain scrutiny and stimulated reassessment of sourcing, manufacturing footprint, and component strategies across the mHealth ecosystem. Tariff-driven input cost pressure has encouraged manufacturers to evaluate nearshoring options, diversify supplier bases, and redesign product bill of materials to reduce exposure to affected components. In parallel, device OEMs and contract manufacturers are placing greater emphasis on supply chain resilience, inventory buffering, and alternative logistics routes to mitigate potential disruptions.
Beyond direct cost implications, tariffs influence strategic decisions that shape partnerships and go-to-market planning. For example, firms that depend on global components for sensors, wireless modules, or semiconductor subsystems are recalibrating procurement timelines and validating substitute suppliers to preserve design integrity. Service providers and app developers are also attentive to device availability and certification timelines because hardware constraints can delay deployments of integrated solutions. In response, many organizations are accelerating standardization initiatives, modularizing designs to accommodate component variability, and increasing transparency with customers about supply chain contingencies. Collectively, these responses reflect a broader industry pivot toward operational agility and geographically diversified supply strategies.
Deep segmentation intelligence describing components, clinical applications, and end-user behaviors to guide product prioritization and go-to-market strategies
A nuanced segmentation approach reveals differentiated adoption drivers and barriers across components, applications, and end users. When considering components, the market encompasses connected medical devices, mHealth apps, mHealth services, and wearable devices. Connected medical devices include subcategories such as blood glucose meters, blood pressure monitors, ECG and heart rate monitors, fetal monitoring devices, neurological monitoring devices, peak flowmeters, pulse oximeters, and sleep apnea monitors, each of which carries unique clinical validation and regulatory demands. mHealth apps span chronic disease management, medication management, personal health records, and women’s health, with chronic disease management further defined by blood pressure and ECG monitoring apps, cancer management apps, diabetes management apps, mental health management apps, and obesity management apps. Women’s health apps cover menstrual health and pregnancy tracking plus postpartum care. mHealth services encompass diagnosis and consultation services, fitness and wellness services, prevention services, remote monitoring services, and treatment services. Wearable devices are largely represented by fitness trackers and smart watches that blend consumer convenience with clinically relevant sensing.
Application-focused segmentation highlights chronic disease management, general health and fitness, remote consultation and telemedicine, and women’s health as distinct demand contexts. Chronic disease management itself includes asthma management, cardiovascular disease management, and diabetes management, each requiring tailored clinical workflows, integration with care teams, and evidence of clinical effectiveness. Women's health applications address menopause management, menstrual health, and pregnancy tracking, where privacy, cultural considerations, and longitudinal data continuity are paramount. From an end-user perspective, stakeholders include healthcare payers, healthcare providers, and patients, with providers comprised of clinic and hospital settings; each end user values different outcomes ranging from cost containment and population health metrics to individual engagement and clinical workflow efficiency. By synthesizing these segmentation lenses, product and commercial strategies can be aligned to match specific clinical use cases, regulatory thresholds, and buyer motivations.
Regional dynamics and operational considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and commercialization success
Regional dynamics reveal diverse opportunity sets and regulatory landscapes that shape commercialization and operational choices. In the Americas, market dynamics are driven by integrated payer-provider systems, a focus on value-based care models, and heavy investment in telehealth infrastructure; stakeholders here prioritize interoperability with existing electronic health records and evidence generation that supports reimbursement conversations. Europe, Middle East & Africa presents a patchwork of national regulatory approaches and procurement mechanisms where privacy regulations and national health system priorities can affect adoption timelines; innovative reimbursement pilots often coexist with conservative procurement cycles, making local partnerships and clinical champions crucial for scaling. Asia-Pacific exhibits heterogeneous maturity across markets, with advanced digital health ecosystems in some high-income markets and rapid adoption of mobile-first health services in emerging economies, where scalability and cost-efficient deployment are central considerations.
Consequently, regional go-to-market strategies should factor in local regulatory frameworks, reimbursement pathways, and health system architectures. In addition, cultural expectations around data privacy and patient engagement must be addressed through localized user experience design and transparent governance practices. Strategic entrants will often adopt a phased approach, demonstrating clinical impact in targeted geographies before scaling broadly, while also investing in regional partnerships to navigate distribution, certification, and payer negotiation complexities.
Corporate strategic patterns revealing how clinical validation, partnerships, and platform architectures are shaping competitive advantage among mHealth providers
Companies across the mHealth landscape are differentiating through a combination of clinical credibility, platform scale, and partnership ecosystems. Market incumbents emphasize regulatory compliance and integrated hardware-software offerings to serve clinical workflows, investing in long-form clinical validation and payer engagement. Agile technology companies are focusing on modular software platforms, developer ecosystems, and rapid iteration to capture developer mindshare and integrate with diverse device makers. Start-ups typically pursue focused use cases where a narrow clinical question or user need enables faster evidence generation and customer acquisition.
Strategic moves include cross-sector collaborations that combine device expertise with analytics and care management capabilities, as well as licensing or OEM relationships that embed software in partner devices. Investment in clinical studies, real-world evidence generation, and interoperability certifications continues to be a critical differentiator for companies seeking widespread adoption. Additionally, firms that deliver repeatable service models and strong implementation playbooks for providers and payers are better positioned to translate pilot success into long-term contracts. Ultimately, the competitive landscape rewards organizations that can bridge clinical rigor with operational scalability and compelling patient experiences.
Practical strategic imperatives for market leaders to scale evidence, ensure interoperability, and build resilient supply and partnership models for long-term growth
Industry leaders should prioritize several actionable moves to convert market momentum into sustainable growth. First, establish cross-functional clinical evidence programs that integrate regulatory strategy, health economics, and real-world data collection from the outset, thereby reducing time to credible adoption by providers and payers. Second, design product architectures that separate hardware-dependent functionality from cloud-based analytics so that modular updates and supplier substitutions can be executed without major redesign. Third, cultivate payer and provider partnerships through pilot programs that demonstrate measurable outcomes and operational feasibility, and use these pilots to co-create reimbursement pathways.
In addition, focus on interoperability and standards adoption to reduce integration friction with electronic health records and device management platforms, and invest in privacy-by-design principles to build patient trust. From an operational standpoint, diversify supplier relationships and explore regional sourcing strategies to mitigate trade-related risks while retaining manufacturing quality. Finally, invest in user experience and behavioral design to maximize adherence and engagement, because even clinically effective solutions will fail to deliver value if patients do not sustain use. Executing on these priorities will require aligned leadership, cross-disciplinary capabilities, and disciplined program management.
A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory review, and cross-regional analysis to produce action-oriented insights
The research methodology underpinning these insights integrates multi-source qualitative and quantitative approaches to capture technology, clinical, regulatory, and commercial dimensions. Primary interviews with clinicians, health system leaders, payers, and product leaders were triangulated with secondary sources, regulatory filings, and peer-reviewed literature to ensure balanced perspectives. An emphasis was placed on real-world implementation experiences and case-based learning to illuminate operational barriers and facilitators that are not always apparent in headline technology descriptions.
Analytical frameworks included segmentation mapping across component, application, and end-user dimensions, cross-regional comparative analysis to surface regulatory and market access differentials, and thematic synthesis of corporate strategies and partnership models. Data quality controls focused on corroborating claims across multiple stakeholder interviews and validating technical assertions with subject-matter experts. Where applicable, findings were stress-tested against plausible operational scenarios to assess sensitivity to supply chain disruptions, regulatory shifts, and changes in reimbursement practices. This mixed-methods approach aims to provide robust, action-oriented intelligence for decision-makers.
A strategic synthesis of clinical, technological, and operational priorities that will determine which organizations capture sustainable value in the evolving mHealth ecosystem
In conclusion, the mHealth landscape is at an inflection point where clinical-grade sensing, software intelligence, and service delivery models are coalescing to extend care across settings. The propensity for adoption will hinge on the ability of solutions to demonstrate clinical value, integrate seamlessly into care workflows, and maintain privacy and security assurances that earn stakeholder trust. Operational resilience, particularly in sourcing and supply chain design, has risen to the forefront of strategic planning due to trade dynamics and component concentration risks.
Moving forward, successful organizations will be those that combine rigorous evidence generation with modular technology architectures, robust partnerships across the care ecosystem, and localized go-to-market strategies that respect regional regulatory and cultural nuances. By aligning product development, clinical validation, and commercial models around demonstrated outcomes, companies can transition pilot successes into scalable deployments that deliver measurable benefits for patients, providers, and payers.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of wearable biosensor data into personalized mobile health management plans
- 5.2. Implementation of AI-driven predictive analytics for remote chronic condition monitoring
- 5.3. Growth of telehealth platforms offering multilingual video consultations for diverse populations
- 5.4. Adoption of gamified mobile applications to improve long-term patient medication adherence
- 5.5. Emergence of blockchain-enabled secure patient data sharing across mHealth ecosystems
- 5.6. Expansion of mobile mental health support programs featuring real-time therapist chat functions
- 5.7. Rise of voice-enabled virtual assistants in mobile health apps for elderly user interfaces
- 5.8. Development of 5G-enabled mobile imaging services for faster diagnostics and remote consultations
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. mHealth Market, by Component
- 8.1. Connected Medical Devices
- 8.1.1. Blood Glucose Meters
- 8.1.2. Blood Pressure Monitors
- 8.1.3. ECG/Heart Rate Monitors
- 8.1.4. Fetal Monitoring Devices
- 8.1.5. Neurological Monitoring Devices
- 8.1.6. Peak Flowmeters
- 8.1.7. Pulse Oximeters
- 8.1.8. Sleep Apnea Monitors
- 8.2. mHealth Apps
- 8.2.1. Chronic Disease Management Apps
- 8.2.1.1. Blood Pressure and ECG Monitoring Apps
- 8.2.1.2. Cancer Management Apps
- 8.2.1.3. Diabetes Management Apps
- 8.2.1.4. Mental Health Management Apps
- 8.2.1.5. Obesity Management Apps
- 8.2.2. Medication Management Apps
- 8.2.3. Personal Health Record Apps
- 8.2.4. Women’s Health Apps
- 8.2.4.1. Menstrual Health
- 8.2.4.2. Pregnancy Tracking & Postpartum Care
- 8.3. mHealth Services
- 8.3.1. Diagnosis & Consultation Services
- 8.3.2. Fitness & Wellness Services
- 8.3.3. Prevention Services
- 8.3.4. Remote Monitoring Services
- 8.3.5. Treatment Services
- 8.4. Wearable Devices
- 8.4.1. Fitness Trackers
- 8.4.2. Smart Watches
- 9. mHealth Market, by Application
- 9.1. Chronic Disease Management
- 9.1.1. Asthma Management
- 9.1.2. Cardiovascular Disease Management
- 9.1.3. Diabetes Management
- 9.2. General Health & Fitness
- 9.3. Remote Consultation & Telemedicine
- 9.4. Women's Health
- 9.4.1. Menopause Management
- 9.4.2. Menstrual Health
- 9.4.3. Pregnancy Tracking
- 10. mHealth Market, by End-User
- 10.1. Healthcare Payers
- 10.2. Healthcare Providers
- 10.2.1. Clinics
- 10.2.2. Hospitals
- 10.3. Patients
- 11. mHealth Market, by Region
- 11.1. Americas
- 11.1.1. North America
- 11.1.2. Latin America
- 11.2. Europe, Middle East & Africa
- 11.2.1. Europe
- 11.2.2. Middle East
- 11.2.3. Africa
- 11.3. Asia-Pacific
- 12. mHealth Market, by Group
- 12.1. ASEAN
- 12.2. GCC
- 12.3. European Union
- 12.4. BRICS
- 12.5. G7
- 12.6. NATO
- 13. mHealth Market, by Country
- 13.1. United States
- 13.2. Canada
- 13.3. Mexico
- 13.4. Brazil
- 13.5. United Kingdom
- 13.6. Germany
- 13.7. France
- 13.8. Russia
- 13.9. Italy
- 13.10. Spain
- 13.11. China
- 13.12. India
- 13.13. Japan
- 13.14. Australia
- 13.15. South Korea
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2024
- 14.2. FPNV Positioning Matrix, 2024
- 14.3. Competitive Analysis
- 14.3.1. AgaMatrix Inc.
- 14.3.2. AirStrip Technologies, Inc.
- 14.3.3. Akili Interactive Labs
- 14.3.4. AliveCor, Inc.
- 14.3.5. Amazon Web Services, Inc.
- 14.3.6. Apple Inc.
- 14.3.7. AT&T Inc.
- 14.3.8. Biofourmis Inc.
- 14.3.9. Boston Scientific Corporation
- 14.3.10. Cisco Systems, Inc.
- 14.3.11. Cognoa, Inc.
- 14.3.12. eMed Healthcare UK Ltd
- 14.3.13. Google LLC by Alphabet Inc.
- 14.3.14. iHealth Lab Inc.
- 14.3.15. International Business Machines Corporation
- 14.3.16. Johnson & Johnson Services, Inc.
- 14.3.17. Koninklijke Philips N.V.
- 14.3.18. Lumeon Ltd.
- 14.3.19. Medtronic PLC
- 14.3.20. OMRON HEALTHCARE , INC
- 14.3.21. Oracle Corporation
- 14.3.22. Qualcomm Technologies, Inc.
- 14.3.23. Samsung Electronics Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
